📋 Tender Overview
The subject of this publication is the conclusion of non-exclusive discount agreements according to § 130a Abs. 8 SGB V for pharmaceuticals containing the active ingredient Brivaracetam (ATC code according to WHO: N03AX23), limited to the dosage form of film-coated tablets. The contract will be concluded within the framework of an Open-House model, meaning that the contract conclusion is open to all interested pharmaceutical companies during the participation period, provided they meet the participation requirements and accept them. This implies that individual contract negotiations will not be conducted and exclusivity is not granted. It is noted that the purchase quantity is unknown, as it depends on demand and the development of the insured population, the prescribing behavior of doctors, and the dispensing and stocking behavior of public pharmacies. Minimum purchase quantities are therefore not guaranteed. Brivaracetam, film-coated tablets